What Is Mounjaro (Tirzepatide)?
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication developed by Eli Lilly that represents a genuine pharmacological advance over the prior generation of incretin-based diabetes and obesity drugs. Where GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) activate a single receptor, tirzepatide is a dual agonist — it simultaneously activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual action has produced clinical trial results that have consistently outperformed semaglutide head-to-head, making tirzepatide one of the most consequential drugs in the treatment of type 2 diabetes and obesity in decades.
The Dual Mechanism: Why GIP + GLP-1 May Work Better
To understand tirzepatide, it helps to understand what GIP adds to the picture. GIP, like GLP-1, is an incretin hormone released after eating. Both hormones stimulate insulin secretion in response to elevated blood glucose. For years, GIP was considered a lesser contributor to the incretin effect — and some research even suggested that GIP receptor agonism might impair the GLP-1 response. Tirzepatide's development challenged these assumptions.
The current understanding of tirzepatide's dual action includes:
- Enhanced insulin secretion: Activating both GIP and GLP-1 receptors on pancreatic beta cells may produce synergistic insulin release, exceeding what either receptor can accomplish alone.
- Adipose tissue effects via GIP: GIP receptors are expressed on fat cells (adipocytes). GIP receptor activation appears to improve how adipose tissue handles fat storage and energy balance, potentially contributing to tirzepatide's superior weight loss compared to GLP-1-only agents.
- Overlapping GLP-1 benefits: Tirzepatide retains all the benefits of GLP-1 agonism — glucagon suppression, gastric emptying delay, and central appetite suppression — while adding GIP's complementary effects.
SURPASS Trials: Diabetes Evidence
The SURPASS clinical trial program evaluated tirzepatide in type 2 diabetes across multiple patient populations. In SURPASS-2, the most pivotal comparison, tirzepatide was tested head-to-head against semaglutide 1 mg (the standard Ozempic diabetes dose) in over 1,800 patients. At the highest tirzepatide dose studied, A1C reduction was significantly greater than semaglutide, and weight loss was approximately 5–6 kg more. These results, published in the New England Journal of Medicine in 2021, established tirzepatide as the most effective non-insulin glucose-lowering drug ever approved and supported Mounjaro's FDA approval in May 2022.
SURMOUNT Trials: Obesity Evidence and Zepbound
In November 2023, the FDA approved tirzepatide for chronic weight management under the separate brand name Zepbound. The pivotal SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight without type 2 diabetes. After 72 weeks, participants at the highest dose lost an average of approximately 22.5% of body weight — a result that exceeded anything previously achieved with a non-surgical, pharmacological intervention and surpassed Wegovy's STEP 1 result of ~15%.
SURMOUNT-5, a head-to-head comparison of tirzepatide versus semaglutide 2.4 mg (Wegovy doses) in adults with obesity, found tirzepatide produced approximately 47% more weight loss than semaglutide — roughly 20% vs 14% of body weight — over 72 weeks.
Mounjaro vs. Zepbound: Same Drug, Different Indications
| Brand | Indication | Patients |
|---|---|---|
| Mounjaro | Type 2 diabetes glycemic control | Adults with T2D |
| Zepbound | Chronic weight management; OSA treatment | Adults with obesity/overweight + comorbidity |
Mounjaro and Zepbound contain identical active ingredients at identical doses — the difference is the FDA-approved indication on the label. Prescribing one off-label for the other's indication occurs in practice, particularly during supply constraints, but patients should understand that insurance coverage is often tied to the specific approved indication.
Side Effects
Gastrointestinal effects
Nausea, vomiting, diarrhea, and constipation mirror the GI side effect profile of other GLP-1 agonists and are the most common reasons patients reduce doses or discontinue treatment. A gradual titration schedule starting at the lowest available dose and increasing at 4-week intervals is standard practice to minimize GI intolerance.
THYROID C-CELL TUMORS (BLACK BOX WARNING): Tirzepatide caused thyroid C-cell tumors in rodents at clinically relevant exposures. Relevance to humans is not established. Mounjaro and Zepbound are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2).
PANCREATITIS: Acute pancreatitis has been reported with GIP/GLP-1 receptor agonists. Discontinue immediately if pancreatitis is suspected; do not restart if confirmed. Report severe, persistent abdominal pain to your provider.
Gallbladder disease
Rapid weight loss is associated with increased risk of gallstone formation and gallbladder disease. Patients who develop symptoms suggestive of gallbladder problems (right upper abdominal pain, especially after eating) should be evaluated promptly.
Want to compare Mounjaro to Ozempic, Wegovy, or other GLP-1 medications?
Compare MedicationsFrequently Asked Questions
Head-to-head clinical trials have consistently shown tirzepatide (Mounjaro) to produce greater A1C reduction and greater weight loss than semaglutide (Ozempic) at standard diabetes doses, and greater weight loss than Wegovy (the higher-dose semaglutide) in the SURMOUNT-5 obesity trial. "Better" in a clinical sense depends on individual goals, tolerability, and the specific clinical outcome being measured. Both are highly effective; the choice between them is appropriately made with a healthcare provider who can weigh individual factors including insurance coverage, prior GI tolerability, and comorbidities.
Mounjaro and Zepbound are the same drug (tirzepatide) manufactured by Eli Lilly but sold under different brand names for different FDA-approved indications. Mounjaro is approved for type 2 diabetes management. Zepbound is approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities, and also for obstructive sleep apnea. The specific brand prescribed may affect insurance coverage depending on your insurer's formulary and what indication you are being treated for.
Tirzepatide is a synthetic peptide that activates two gut hormone receptors simultaneously: the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Both receptors are involved in insulin secretion and metabolic regulation. By activating both, tirzepatide stimulates glucose-dependent insulin release from the pancreas, suppresses glucagon, slows gastric emptying, reduces appetite through brain pathways, and appears to improve fat cell metabolism via GIP receptor effects. The combined action of both receptors produces metabolic improvements beyond what GLP-1 agonism alone achieves.